Haematologica Reports 2005; 1(issue 8):
72-76[prev][index][next]
Tipifarnib in hematologic malignancies
Harousseau J-L
Department of Hematology Hotel Dieu Nantes, France
I. Rationale for using Tipifarnib in hematologic
malignancies
Signal transduction pathways regulate the cell processes of growth
differentiation and survival. Aberrations in signal transduction
pathways can lead to increased cell proliferation, apoptosis
inhibition, increased angiogenesis, tissue invasion and metastasis.
Most human neoplasias have aberrant signal transduction elements.
Therefore signal transduction inhibitors represent a new class of
compounds potentially active in cancer treatment. These agents
target proteins or pathways that are involved in the pathogenesis
of malignancies. [>Read full article in
PDF]
